Last reviewed · How we verify
4-Demethyl-4-cholestryloxycarbonylpenclomedine
4-Demethyl-4-cholestryloxycarbonylpenclomedine is a Topoisomerase II inhibitor Small molecule drug developed by DEKK-TEC, Inc.. It is currently in Phase 2 development for Metastatic breast cancer, Metastatic ovarian cancer. Also known as: DM-CHOC-PEN.
4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II.
4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II. Used for Metastatic breast cancer, Metastatic ovarian cancer.
At a glance
| Generic name | 4-Demethyl-4-cholestryloxycarbonylpenclomedine |
|---|---|
| Also known as | DM-CHOC-PEN |
| Sponsor | DEKK-TEC, Inc. |
| Drug class | Topoisomerase II inhibitor |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This inhibition leads to DNA damage and ultimately cell death in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the formation of DNA-protein crosslinks and the activation of apoptosis pathways.
Approved indications
- Metastatic breast cancer
- Metastatic ovarian cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- DM-CHOC-PEN for Brain Tumors in AYA Subjects (PHASE2)
- DM-CHOC-PEN Plus Radiation for Brain Tumors (PHASE1)
- Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors (PHASE2)
- A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers
- Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer (PHASE1)
- Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer" (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine CI brief — competitive landscape report
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine updates RSS · CI watch RSS
- DEKK-TEC, Inc. portfolio CI
Frequently asked questions about 4-Demethyl-4-cholestryloxycarbonylpenclomedine
What is 4-Demethyl-4-cholestryloxycarbonylpenclomedine?
How does 4-Demethyl-4-cholestryloxycarbonylpenclomedine work?
What is 4-Demethyl-4-cholestryloxycarbonylpenclomedine used for?
Who makes 4-Demethyl-4-cholestryloxycarbonylpenclomedine?
Is 4-Demethyl-4-cholestryloxycarbonylpenclomedine also known as anything else?
What drug class is 4-Demethyl-4-cholestryloxycarbonylpenclomedine in?
What development phase is 4-Demethyl-4-cholestryloxycarbonylpenclomedine in?
What are the side effects of 4-Demethyl-4-cholestryloxycarbonylpenclomedine?
What does 4-Demethyl-4-cholestryloxycarbonylpenclomedine target?
Related
- Drug class: All Topoisomerase II inhibitor drugs
- Target: All drugs targeting Topoisomerase II
- Manufacturer: DEKK-TEC, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Indication: Drugs for Metastatic ovarian cancer
- Also known as: DM-CHOC-PEN